HRTX
Heron Therapeutics, Inc.
Biotechnology · Healthcare · United States
0.28
close · 2026-10-30
value
7
cheaper than peers7
quality
25
stronger fundamentals25
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 0.35× | 100 |
| earnings yield, 1 year ago | -32.4% | 36 |
| earnings yield, latest year | -43.2% | 24 |
| price to book | 8.96× | 22 |
| cash flow yield, 1 year ago | -46.0% | 19 |
| cash flow yield, latest year | -52.9% | 16 |
| cash flow yield, 2 years ago | -114.4% | 8 |
| earnings yield, 2 years ago | -288.1% | 7 |
| cash flow yield, 3 years ago | -282.1% | 5 |
| earnings yield, 3 years ago | -601.4% | 3 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -5.4% | 76 |
| revenue growth | 1.3% | 36 |
| debt to equity | 2147.6% | 2 |
3 of 4 measures available
Facts
| market cap | $53M |
| free cash flow | -$8.8M |
| employees | 128 |
| first trade | 1987-08-26 |
| next earnings | 2026-11-09 |
| fundamentals updated | 2026-08-19 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.12 | -0.09 | -0.80 | -1.67 |
| free cash flow | -$27.9M | -$24.2M | -$60.3M | -$148.7M |
| net income | -$20.2M | -$13.6M | -$110.6M | -$182.0M |
| revenue | $154.9M | $144.3M | $127.0M | $107.7M |
| unusual items | -$11.3M | $0 | $0 | not reported |